Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:40:52.415Z.
Consensus retrieved: 2026-10-06T08:59:04.289Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:40:52.415Z.
Quote observation: 2026-10-06T13:30:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8bc85e2d5351a47333dd9131f39a7cf6b6d5f02586c5202dd123a5ad4370615
Forward PE Ratio (N/A) = Dated Quote Price ($2.63) / Consensus Forward EPS ($-0.26)
FORWARD PE RATIO
N/A
Apyx Medical Corporation
Market Cap
$110.75M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Apyx Medical Corporation (APYX) | $110.75M | N/A |
| Immunic, Inc. (IMUX)vs › | $110.06M | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.02M | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $109.38M | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.02M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.35M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.44M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.47M | 5.08 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.63, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.27 | $-0.27 – $-0.26 | 4 | n/m |
| 2027-12-31 | $-0.25 | $-0.26 – $-0.25 | 4 | n/m |
| 2028-12-31 | $-0.10 | $-0.11 – $-0.09 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
